REGN: Expanding Immunology And Gene Therapy Will Support Future Upside

Regeneron's analyst price target has been adjusted slightly higher to $875.31 from $873.78, as analysts factor in updated assumptions around revenue growth, profitability, and future P/E multiples following a mix of recent target hikes and trims across the Street.

Analyst Commentary

Recent Street research on Regeneron Pharmaceuticals shows a mix of optimism and caution, reflected in a series of price target raises and trims clustered over the past few months. For you as an investor, the key questions center on how confident analysts are in the growth outlook, how they see execution risk around the pipeline, and how they are framing valuation at current trading levels.

Bullish Takeaways

Bullish analysts see room for the shares to better reflect expected profits from Dupixent over the near and medium term, with some research arguing that current pricing of that franchise is too conservative relative to their revenue and margin assumptions.
Several recent target hikes point to perceived upside from the broader pipeline, with specific reference to programs like Lynozyfic, which some researchers view as undervalued in current models and a potential support for longer term growth expectations.
Some firms raising targets highlight confidence in Regeneron's R&D engine, citing potential medium term growth contributions from Dupixent, the broader pipeline, and the repayment from Sanofi, which they factor into their cash flow and capital allocation outlooks.
Initiation and assumption reports with Overweight style views suggest that, for these bullish analysts, the current P/E and implied growth multiples do not fully capture what they see as underappreciated indication expansion for Dupixent and future pipeline execution.

Bearish Takeaways

Bearish analysts trimming price targets point to valuation risk, signaling that, at current levels, their models support less upside once they adjust assumptions on key products and potential competitive or regulatory headwinds.
Some research flags ongoing Eylea headwinds as a factor that could weigh on how the stock trades, leading them to apply more conservative revenue trajectories and, in turn, more muted target prices relative to prior estimates.
There is caution around Dupixent loss of exclusivity uncertainty, with certain analysts assuming a discount in their multiples or longer term cash flow outlooks to reflect potential pressure on pricing and volumes over time.
Where targets are reduced rather than raised, bearish analysts are effectively signaling higher execution risk on the current growth plan, choosing to temper expectations around how quickly pipeline assets and new indications might translate into earnings power.

What’s in the News

The U.S. FDA granted accelerated approval for Otarmeni, Regeneron’s in vivo gene therapy for ultra rare OTOF related hearing loss. The company indicated it will make the therapy available at no cost to clinically eligible patients in the U.S., while a Bloomberg report notes Regeneron agreed to lower prices as the gene therapy was approved (company release, Bloomberg).
Regeneron and Sanofi received U.S. FDA approval for Dupixent to treat children aged 2 to 11 years with chronic spontaneous urticaria who remain symptomatic on antihistamines. This extends an existing CSU label that previously covered adults and adolescents (company release).
The European Commission approved Dupixent for moderate to severe chronic spontaneous urticaria in children aged 2 to 11 years with inadequate response to antihistamines and who are naive to anti IgE therapy. This further broadens the medicine’s pediatric reach in CSU (company release).
The U.S. FDA approved extended dosing intervals for EYLEA HD up to every 20 weeks for certain patients with wet age related macular degeneration and diabetic macular edema after one year of successful treatment, and updated the label to include 96 week data from the PULSAR and PHOTON trials (company release).
Regeneron announced a new share repurchase program authorizing up to US$3,000m of common stock with no stated time limit. The company also updated that by March 31, 2026, it had repurchased 3,579,576 shares for US$2,308.44m under a prior authorization, equivalent to 3.46% of shares (company filing).

Valuation Changes

Fair Value: Updated slightly higher to $875.31 from $873.78, representing a modest upward revision in the model output.
Discount Rate: Adjusted to 7.21% from 7.13%, reflecting a small increase in the required return used in the analysis.
Revenue Growth: Updated assumption to 9.36% from 9.20%, indicating a modestly higher expected top line growth rate in the model.
Net Profit Margin: Reset to 31.18% from 32.28%, representing a small reduction in projected profitability levels.
Future P/E: Updated to 17.55x from 16.75x, indicating a slightly higher valuation multiple applied to forward earnings in the revised assumptions.

17 views

Key Takeaways

Expanding pipeline, new indications, and emerging market access position the company for sustained revenue growth and increased long-term earnings.
Ongoing R&D investment and advanced manufacturing provide cost advantages and margin protection amid shifts toward breakthrough technologies and personalized medicine.
Heavy reliance on EYLEA amid intensifying competition, regulatory delays, and pricing pressures threatens revenue sustainability, while pipeline and market uncertainties cloud future growth prospects.

Catalysts

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.What are the underlying business or industry changes driving this perspective?

Regeneron's broad and advancing pipeline-including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity-positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.
Rapid growth and expansion of Dupixent (with new indications in COPD, CSU, and bullous pemphigoid) has significantly increased the addressable patient population, but only a small fraction of eligible patients are currently being treated, leaving substantial runway for volume growth, especially as global healthcare access expands-supportive of higher long-term revenues and margins.
The successful ramp of EYLEA HD, which is gaining physician adoption due to its clinical profile and durability, along with anticipated regulatory approvals for label enhancements (pending resolution of manufacturing site issues), could help offset patent/biosimilar pressures on legacy EYLEA, supporting stabilization and potential growth in core revenue and sustaining healthy margins over the next several years.
Significant reinvestment in internal R&D, advanced manufacturing, and in-house biologics and gene therapy platforms provides Regeneron with cost advantages and rapid scalability, enhancing margin protection as the industry accelerates adoption of new biotechnologies (AI, big data, CRISPR) and as regulatory pathways become more favorable for differentiated breakthrough therapies.
Expansion into high-growth indications such as obesity and cardiometabolic diseases (via GLP-1/GIP, novel antibody combinations) and strategic development for emerging market access (benefiting from increased global healthcare spending) create new multi-billion-dollar revenue streams likely underappreciated by the market, supporting higher long-term earnings and revenue diversification.

Regeneron Pharmaceuticals Earnings and Revenue Growth

Regeneron Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Regeneron Pharmaceuticals's revenue will grow by 9.4% annually over the next 3 years.
Analysts assume that profit margins will increase from 29.6% today to 31.2% in 3 years time.
Analysts expect earnings to reach $6.1 billion (and earnings per share of $57.62) by about May 2029, up from $4.4 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $7.6 billion in earnings, and the most bearish expecting $4.9 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.7x on those 2029 earnings, up from 16.1x today. This future PE is greater than the current PE for the US Biotechs industry at 17.3x.
Analysts expect the number of shares outstanding to decline by 1.39% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.21%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

EYLEA faces ongoing branded and biosimilar competition as well as continued unit demand declines, with management explicitly cautioning that pricing, patient affordability issues, and competitive pressures are expected to negatively impact future U.S. net product sales; this poses a risk of significant revenue and earnings erosion as EYLEA represents a large portion of current revenue.
Delays in regulatory approvals for EYLEA HD enhancements-due to FDA observations at key third-party manufacturing sites (Catalent/Novo Nordisk Indiana)-create near-term uncertainty and may postpone critical product improvements and label expansions essential to offset competitive headwinds, pressuring near
to long-term revenue and margin growth.
The company is significantly increasing internal R&D and U.S. manufacturing investments (over $7 billion), but with pipeline skepticism from analysts regarding the commercial value of late-stage assets relative to high annual R&D spend, there is risk of insufficient pipeline diversification or failure to generate new blockbusters, potentially limiting future earnings growth and compressing net margins.
External policy and pricing risks such as Medicare's MFN (Most Favored Nation) pricing, increased global pressure on drug prices, and uncertainty around reimbursement-particularly for key U.S. products like EYLEA-could compress net selling prices and reduce overall revenue and margins, especially if Regeneron cannot influence pricing in OUS (outside U.S.) markets managed by partners like Bayer.
The branded anti-VEGF market is experiencing share erosion to lower-cost alternatives (e.g., Avastin) due to patient affordability and assistance funding gaps, while ongoing and heightened biosimilar competition further threaten market share for established franchises, putting long-term revenue and operating income under sustained downward pressure.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $875.31 for Regeneron Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1057.0, and the most bearish reporting a price target of just $730.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $19.5 billion, earnings will come to $6.1 billion, and it would be trading on a PE ratio of 17.7x, assuming you use a discount rate of 7.2%.
Given the current share price of $701.42, the analyst price target of $875.31 is 19.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Regeneron Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead